# OnCo record paper-gog-240-bevacizumab-cervical-nejm-2014 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-gog-240-bevacizumab-cervical-nejm-2014" ;
  schema:name "GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer"@en ;
  schema:description "Adding the anti-angiogenic antibody bevacizumab to chemotherapy lengthened survival by almost four months in recurrent or metastatic cervical cancer, the first targeted drug to improve survival in a gynaecological cancer."@en ;
  schema:url <https://onco.cc/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1309748>, <https://pubmed.ncbi.nlm.nih.gov/24552320/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1309748> ;
  schema:datePublished "2014"^^xsd:gYear ;
  schema:author "Tewari KS, Sill MW, Long HJ, et al." ;
  onco:cancers <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/> ;
  onco:journals <https://onco.cc/journals/nejm/> .